Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Rubius Therapeutics, Inc. (RUBY)
|
Add to portfolio |
|
|
|
| Price: |
$10.17
| | Metrics |
| OS: |
90.4
|
M
| |
-1187
|
% ROE
|
| Market cap: |
$919
|
M
| |
-12608
|
% ROIC
|
|
Net cash:
|
$14.9
|
M
| |
$0.16
|
per share
|
|
EV:
|
$904
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($121)
|
M
| |
|
|
|
EBIT
|
($127)
|
M
| |
|
|
| EPS |
($1.99)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 93.9 | 44.1 | 0.0 |
| Revenue growth | | | | -100.0% | 113.0% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 93.9 | 44.1 | 0.0 |
| Gross margin | | | | | 100.0% | 100.0% | |
| Research and development | 96.4 | 141.6 | 116.1 | 112.4 | 51.8 | 21.2 | 8.4 |
| General and administrative | 30.8 | 53.0 | 50.3 | 57.2 | 39.9 | 22.0 | 2.4 |
| EBIT | -127.2 | -194.6 | -166.4 | -169.6 | -91.7 | -43.3 | -10.9 |
| EBIT margin | | | | | -97.7% | -98.2% | |
| Pre-tax income | -179.7 | -196.5 | -167.7 | -163.5 | -89.2 | -43.8 | -11.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -179.7 | -196.5 | -167.7 | -163.5 | -89.2 | -44.5 | -11.8 |
| Net margin | | | | | -95.0% | -101.0% | |
| |
| Diluted EPS | ($1.99) | ($2.23) | ($2.08) | ($2.08) | ($2.27) | ($5.55) | ($1.63) |
| Shares outstanding (diluted) | 90.3 | 88.0 | 80.6 | 78.7 | 39.3 | 8.0 | 7.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|